Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

UK trial of the Osseointegrated Prosthesis for the Rehabilitation for Amputees: 1995-2018.

Matthews DJ, Arastu M, Uden M, Sullivan JP, Bolsakova K, Robinson K, Sooriakumaran S, Ward D.

Prosthet Orthot Int. 2019 Feb;43(1):112-122. doi: 10.1177/0309364618791616. Epub 2018 Aug 16.

PMID:
30112981
2.

Function of the unaffected arms of children with neonatal brachial plexus injuries.

Matthews DJ.

Eur J Paediatr Neurol. 2018 Jul;22(4):581. doi: 10.1016/j.ejpn.2018.05.014. No abstract available.

PMID:
29887414
3.

Basics of bone metabolism and osteoporosis in common pediatric neuromuscular disabilities.

Yaşar E, Adigüzel E, Arslan M, Matthews DJ.

Eur J Paediatr Neurol. 2018 Jan;22(1):17-26. doi: 10.1016/j.ejpn.2017.08.001. Epub 2017 Aug 10. Review.

PMID:
28830650
4.

Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors.

Rewcastle GW, Kolekar S, Buchanan CM, Gamage SA, Giddens AC, Tsang KY, Kendall JD, Singh R, Lee WJ, Smith GC, Han W, Matthews DJ, Denny WA, Shepherd PR, Jamieson SMF.

Oncotarget. 2017 Jul 18;8(29):47725-47740. doi: 10.18632/oncotarget.17730.

5.

Rehabilitation issues in Charcot-Marie-Tooth disease.

Kenis-Coskun O, Matthews DJ.

J Pediatr Rehabil Med. 2016;9(1):31-4. doi: 10.3233/PRM-160359. Review.

PMID:
26966798
6.

Frequency of botulinum toxin injections for spastic equinus: how much is enough?

Matthews DJ.

Dev Med Child Neurol. 2016 Jul;58(7):657-8. doi: 10.1111/dmcn.12994. Epub 2015 Dec 11. No abstract available.

7.

Fabrication of a Flexible Amperometric Glucose Sensor Using Additive Processes.

Du X, Durgan CJ, Matthews DJ, Motley JR, Tan X, Pholsena K, Árnadóttir L, Castle JR, Jacobs PG, Cargill RS, Ward WK, Conley JF Jr, Herman GS.

ECS J Solid State Sci Technol. 2015;4(4):P3069-P3074. Epub 2015 Feb 18.

8.

Prevalence of Duchenne and Becker muscular dystrophies in the United States.

Romitti PA, Zhu Y, Puzhankara S, James KA, Nabukera SK, Zamba GK, Ciafaloni E, Cunniff C, Druschel CM, Mathews KD, Matthews DJ, Meaney FJ, Andrews JG, Conway KM, Fox DJ, Street N, Adams MM, Bolen J; MD STARnet.

Pediatrics. 2015 Mar;135(3):513-21. doi: 10.1542/peds.2014-2044. Epub 2015 Feb 16. Erratum in: Pediatrics. 2015 May;135(5):945.

9.

The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.

Foster P, Yamaguchi K, Hsu PP, Qian F, Du X, Wu J, Won KA, Yu P, Jaeger CT, Zhang W, Marlowe CK, Keast P, Abulafia W, Chen J, Young J, Plonowski A, Yakes FM, Chu F, Engell K, Bentzien F, Lam ST, Dale S, Yturralde O, Matthews DJ, Lamb P, Laird AD.

Mol Cancer Ther. 2015 Apr;14(4):931-40. doi: 10.1158/1535-7163.MCT-14-0833. Epub 2015 Jan 30.

10.

Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation.

Kim S, Campbell KA, Fox DJ, Matthews DJ, Valdez R; MD STARnet.

J Child Neurol. 2015 Sep;30(10):1275-80. doi: 10.1177/0883073814558120. Epub 2014 Nov 20.

11.

Complementary and alternative medicine for Duchenne and Becker muscular dystrophies: characteristics of users and caregivers.

Zhu Y, Romitti PA, Conway KM, Andrews J, Liu K, Meaney FJ, Street N, Puzhankara S, Druschel CM, Matthews DJ.

Pediatr Neurol. 2014 Jul;51(1):71-7. doi: 10.1016/j.pediatrneurol.2014.02.003. Epub 2014 Feb 15.

12.

Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.

Yu P, Laird AD, Du X, Wu J, Won KA, Yamaguchi K, Hsu PP, Qian F, Jaeger CT, Zhang W, Buhr CA, Shen P, Abulafia W, Chen J, Young J, Plonowski A, Yakes FM, Chu F, Lee M, Bentzien F, Lam ST, Dale S, Matthews DJ, Lamb P, Foster P.

Mol Cancer Ther. 2014 May;13(5):1078-91. doi: 10.1158/1535-7163.MCT-13-0709. Epub 2014 Mar 14.

13.

A Cohort Study Predicts Better Functional Outcomes and Equivalent Patient Satisfaction Following UKR Compared with TKR.

Matthews DJ, Hossain FS, Patel S, Haddad FS.

HSS J. 2013 Feb;9(1):21-4. doi: 10.1007/s11420-012-9326-4. Epub 2013 Jan 24. Erratum in: HSS J. 2013 Jul;9(2):212.

14.

Erratum to: A Cohort Study Predicts Better Functional Outcomes and Equivalent Patient Satisfaction Following UKR Compared with TKR.

Matthews DJ, Hossain FS, Patel S, Haddad FS.

HSS J. 2013 Jul;9(2):212. doi: 10.1007/s11420-013-9329-9. No abstract available.

15.

Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies.

Pantua H, Diao J, Ultsch M, Hazen M, Mathieu M, McCutcheon K, Takeda K, Date S, Cheung TK, Phung Q, Hass P, Arnott D, Hongo JA, Matthews DJ, Brown A, Patel AH, Kelley RF, Eigenbrot C, Kapadia SB.

J Mol Biol. 2013 Jun 12;425(11):1899-1914. doi: 10.1016/j.jmb.2013.02.025. Epub 2013 Feb 28.

16.

Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody.

Potter JA, Owsianka AM, Jeffery N, Matthews DJ, Keck ZY, Lau P, Foung SK, Taylor GL, Patel AH.

J Virol. 2012 Dec;86(23):12923-32. doi: 10.1128/JVI.02052-12. Epub 2012 Sep 19.

17.

Pyrazolopyrimidines as dual Akt/p70S6K inhibitors.

Rice KD, Kim MH, Bussenius J, Anand NK, Blazey CM, Bowles OJ, Canne-Bannen L, Chan DS, Chen B, Co EW, Costanzo S, DeFina SC, Dubenko L, Engst S, Franzini M, Huang P, Jammalamadaka V, Khoury RG, Klein RR, Laird AD, Le DT, Mac MB, Matthews DJ, Markby D, Miller N, Nuss JM, Parks JJ, Tsang TH, Tsuhako AL, Wang Y, Xu W.

Bioorg Med Chem Lett. 2012 Apr 15;22(8):2693-7. doi: 10.1016/j.bmcl.2012.03.011. Epub 2012 Mar 10.

PMID:
22450127
18.

Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors.

Bussenius J, Anand NK, Blazey CM, Bowles OJ, Bannen LC, Chan DS, Chen B, Co EW, Costanzo S, DeFina SC, Dubenko L, Engst S, Franzini M, Huang P, Jammalamadaka V, Khoury RG, Kim MH, Klein RR, Laird D, Le DT, Mac MB, Matthews DJ, Markby D, Miller N, Nuss JM, Parks JJ, Tsang TH, Tsuhako AL, Wang Y, Xu W, Rice KD.

Bioorg Med Chem Lett. 2012 Mar 15;22(6):2283-6. doi: 10.1016/j.bmcl.2012.01.105. Epub 2012 Feb 2.

PMID:
22342124
19.

Botulinum toxin a treatment in children with cerebral palsy: its effects on walking and energy expenditure.

Balaban B, Tok F, Tan AK, Matthews DJ.

Am J Phys Med Rehabil. 2012 Jan;91(1):53-64. doi: 10.1097/PHM.0b013e31823caae1.

PMID:
22157436
20.

Use of complementary and alternative medicine by males with Duchenne or Becker muscular dystrophy.

Nabukera SK, Romitti PA, Campbell KA, Meaney FJ, Caspers KM, Mathews KD, Sherlock SM, Puzhankara S, Cunniff C, Druschel CM, Pandya S, Matthews DJ, Ciafaloni E; MD STARnet.

J Child Neurol. 2012 Jun;27(6):734-40. doi: 10.1177/0883073811426501. Epub 2011 Dec 7.

21.

Pediatric rehabilitation medicine in the USA.

Hurvitz EA, Matthews DJ.

PM R. 2011 Jan;3(1):53-4. doi: 10.1016/j.pmrj.2010.09.013. No abstract available.

22.

Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy.

Matthews DJ, James KA, Miller LA, Pandya S, Campbell KA, Ciafaloni E, Mathews KD, Miller TM, Cunniff C, Meaney FJ, Druschel CM, Romitti PA, Fox DJ; MD STARnet.

J Child Neurol. 2010 Nov;25(11):1319-24. doi: 10.1177/0883073810362762. Epub 2010 Mar 5.

23.

[Management of spasticity in children with cerebral palsy].

Matthews DJ, Balaban B.

Acta Orthop Traumatol Turc. 2009 Mar-Apr;43(2):81-6. doi: 10.3944/AOTT.2009.081. Turkish.

24.

Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet).

Ciafaloni E, Fox DJ, Pandya S, Westfield CP, Puzhankara S, Romitti PA, Mathews KD, Miller TM, Matthews DJ, Miller LA, Cunniff C, Druschel CM, Moxley RT.

J Pediatr. 2009 Sep;155(3):380-5. doi: 10.1016/j.jpeds.2009.02.007. Epub 2009 Apr 25.

25.

An assessment of the accuracy and usability of a novel optical wound measurement system.

Bowling FL, King L, Fadavi H, Paterson JA, Preece K, Daniel RW, Matthews DJ, Boulton AJ.

Diabet Med. 2009 Jan;26(1):93-6. doi: 10.1111/j.1464-5491.2008.02611.x.

PMID:
19125768
26.

A surgical technique to prevent maceration of tissue during excision of skin lesions.

Matthews DJ, Ismail A, Ismail-Koch H, Chalstrey SE.

J Plast Reconstr Aesthet Surg. 2009 Feb;62(2):205. doi: 10.1016/j.bjps.2008.07.034. Epub 2008 Nov 18. No abstract available.

PMID:
19019750
27.

EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.

Trowe T, Boukouvala S, Calkins K, Cutler RE Jr, Fong R, Funke R, Gendreau SB, Kim YD, Miller N, Woolfrey JR, Vysotskaia V, Yang JP, Gerritsen ME, Matthews DJ, Lamb P, Heuer TS.

Clin Cancer Res. 2008 Apr 15;14(8):2465-75. doi: 10.1158/1078-0432.CCR-07-4367.

28.

Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo.

Matthews DJ, Yakes FM, Chen J, Tadano M, Bornheim L, Clary DO, Tai A, Wagner JM, Miller N, Kim YD, Robertson S, Murray L, Karnitz LM.

Cell Cycle. 2007 Jan 1;6(1):104-10. Epub 2007 Jan 7.

PMID:
17245119
29.

Five-year prospective clinical and radiological results of a new cannulated cemented polished Tri-Taper femoral stem.

Field RE, Singh PJ, Latif AM, Cronin MD, Matthews DJ.

J Bone Joint Surg Br. 2006 Mar;88(3):315-20.

PMID:
16498003
30.

Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.

Balaban B, Matthews DJ, Clayton GH, Carry T.

Am J Phys Med Rehabil. 2005 Nov;84(11):843-50.

PMID:
16244521
32.

High-throughput structural biology in drug discovery: protein kinases.

Stout TJ, Foster PG, Matthews DJ.

Curr Pharm Des. 2004;10(10):1069-82. Review.

PMID:
15078142
33.

Using model-system genetics for drug-based target discovery.

Matthews DJ, Kopczynski J.

Drug Discov Today. 2001 Feb 1;6(3):141-149.

PMID:
11165187
34.

Structures of active and latent PAI-1: a possible stabilizing role for chloride ions.

Stout TJ, Graham H, Buckley DI, Matthews DJ.

Biochemistry. 2000 Jul 25;39(29):8460-9.

PMID:
10913251
35.

T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses.

Townsend MJ, Fallon PG, Matthews DJ, Jolin HE, McKenzie AN.

J Exp Med. 2000 Mar 20;191(6):1069-76.

36.

IL-13 is a susceptibility factor for Leishmania major infection.

Matthews DJ, Emson CL, McKenzie GJ, Jolin HE, Blackwell JM, McKenzie AN.

J Immunol. 2000 Feb 1;164(3):1458-62.

37.

Engineering a soluble extracellular erythropoietin receptor (EPObp) in Pichia pastoris to eliminate microheterogeneity, and its complex with erythropoietin.

Zhan H, Liu B, Reid SW, Aoki KH, Li C, Syed RS, Karkaria C, Koe G, Sitney K, Hayenga K, Mistry F, Savel L, Dreyer M, Katz BA, Schreurs J, Matthews DJ, Cheetham JC, Egrie J, Giebel LB, Stroud RM.

Protein Eng. 1999 Jun;12(6):505-13.

PMID:
10388848
38.

Efficiency of signalling through cytokine receptors depends critically on receptor orientation.

Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, Zhan H, Osslund TD, Chirino AJ, Zhang J, Finer-Moore J, Elliott S, Sitney K, Katz BA, Matthews DJ, Wendoloski JJ, Egrie J, Stroud RM.

Nature. 1998 Oct 1;395(6701):511-6.

PMID:
9774108
39.

Survival and functional outcome of children following severe traumatic brain injury.

Matthews DJ.

Crit Care Med. 1997 Aug;25(8):1272. No abstract available.

PMID:
9267935
40.

Characterization of the receptor binding determinants of granulocyte colony stimulating factor.

Young DC, Zhan H, Cheng QL, Hou J, Matthews DJ.

Protein Sci. 1997 Jun;6(6):1228-36. Erratum in: Protein Sci 1997 Aug;6(8):1787.

41.

Interleukin 4 and interleukin 13: same response, different receptors.

Callard RE, Matthews DJ, Hibbert LM.

Biochem Soc Trans. 1997 May;25(2):451-5. Review. No abstract available.

PMID:
9191134
42.

Homodimerization of erythropoietin receptor by a bivalent monoclonal antibody triggers cell proliferation and differentiation of erythroid precursors.

Schneider H, Chaovapong W, Matthews DJ, Karkaria C, Cass RT, Zhan H, Boyle M, Lorenzini T, Elliott SG, Giebel LB.

Blood. 1997 Jan 15;89(2):473-82.

PMID:
9002949
43.

Regulation of human B cell growth and differentiation: lessons from the primary immunodeficiencies.

Callard RE, Smith SH, Matthews DJ.

Chem Immunol. 1997;67:114-32. Review. No abstract available.

PMID:
9212502
45.

Biological activity of IL-4 and IL-13 on human endothelial cells: functional evidence that both cytokines act through the same receptor.

Kotowicz K, Callard RE, Friedrich K, Matthews DJ, Klein N.

Int Immunol. 1996 Dec;8(12):1915-25.

PMID:
8982776
46.

A sequential dimerization mechanism for erythropoietin receptor activation.

Matthews DJ, Topping RS, Cass RT, Giebel LB.

Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9471-6.

47.
48.

IL-4 and IL-13 receptors: are they one and the same?

Callard RE, Matthews DJ, Hibbert L.

Immunol Today. 1996 Mar;17(3):108-10. Review.

PMID:
8820266
49.

Interfacial metal-binding site design.

Matthews DJ.

Curr Opin Biotechnol. 1995 Aug;6(4):419-24. Review.

PMID:
7579652
50.

Proliferation of MIELIKI a novel t(7;9) early pre-B acute lymphoblastic leukemia cell line is inhibited concomitantly by IL-4 and IL-7.

Renard N, Duvert V, Matthews DJ, Pagés MP, Magaud JP, Manel AM, Pandrau-Garcia D, Philippe N, Banchereau J, Saeland S.

Leukemia. 1995 Jul;9(7):1219-26.

PMID:
7630198

Supplemental Content

Loading ...
Support Center